



- (51) International Patent Classification: *A61P 31/00* (2006.01) *G06Q 50/00* (2012.01)
- (21) International Application Number: PCT/US2016/014020
- (22) International Filing Date: 20 January 2016 (20.01.2016)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 14/600,948 20 January 2015 (20.01.2015) US
- (71) Applicant: **ICPD TECHNOLOGIES, LLC** [US/US]; 43 British American Boulevard, Latham, New York 12110 (US).
- (72) Inventors: **AMBROSE, Paul G.**; c/o ICPD TECHNOLOGIES, LLC, 43 British American Blvd., Latham, New York 12110 (US). **BHAVNANI, Sujata**; c/o ICPD TECHNOLOGIES, LLC, 43 British American Blvd., Latham, New York 12110 (US). **RUBINO, Christopher M.**; c/o ICPD TECHNOLOGIES, LLC, 43 British American Blvd., Latham, New York 12110 (US).
- (74) Agent: **REINKE, Wayne F.**; Heslin Rothenberg Farley & Mesiti P.C., 5 Columbia Circle, Albany, New York 12203 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,

[Continued on next page]

(54) Title: SYSTEM AND METHOD FOR RANKING OPTIONS FOR MEDICAL TREATMENTS

(57) Abstract: A computer system, computer program product and method for determining a probability of attaining a PK-PD target associated with efficacy for a patient that includes a processor obtaining information identifying an infection and based on the information, generating and displaying, by the processor, a list comprising one or more pathogens consistent with the information, generating a list comprising one or more drug therapies utilized to treat the at least one pathogen. The method also includes the processor obtaining, descriptive information relating to a patient and based on the one or more drug therapies, selecting a pharmacokinetic model and the processor applying the pharmacokinetic model and utilizing the information relating to the patient to determine, for each of the one or more drug therapies, a probability of attaining a PK-PD target associated with efficacy for the patient with the infection




FIG 14



TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, **Published:**  
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, — *with international search report (Art. 21(3))*  
LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE,  
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA,  
GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

## SYSTEM AND METHOD FOR RANKING OPTIONS FOR MEDICAL TREATMENTS

### FIELD OF INVENTION

[0001] The Invention relates generally to systems and methods for enabling health care providers to discriminate among potential anti-infective therapies for the treatment of selected infectious diseases.

### BACKGROUND OF INVENTION

[0002] The goal of anti-infective stewardship is to select therapies that optimize the probability of positive outcomes for patients suffering from an infection. The primary focus of anti-infective stewardship is the optimal selection of anti-infective therapy, including dose, dosing interval, and duration. Due to the emergence of anti-infective-resistant pathogens, selecting optimal anti-infective therapy is more complex than at any other time since the advent of penicillin.

### SUMMARY OF INVENTION

[0003] Shortcomings of the prior art are overcome and additional advantages are provided through the provision of a method for improving communication between a patient and a provider, the method includes: obtaining, by a processor, information identifying an infection; based on the information, generating and displaying, by the processor, a list comprising one or more pathogens consistent with the information; obtaining, by the processor, a first indication designating at least one pathogen from the list comprising one or more pathogens; based on at the obtaining of the least one pathogen, generating, by the processor, a list comprising one or more drug therapies utilized to treat the at least one pathogen; obtaining, descriptive information relating to a patient; based on the one or more drug therapies, selecting a pharmacokinetic model; and applying, by the processor, the pharmacokinetic model and utilizing the information relating to the patient to determine, for each of the one or more drug therapies, a probability of attaining a pharmacokinetic-pharmacodynamic (PK-PD) target associated with efficacy for the patient with the infection.

[0004] Computer systems, computer program products and methods relating to one or more aspects of the technique are also described and may be claimed herein. Further, services relating to one or more aspects of the technique are also described and may be claimed herein.

[0005] Additional features are realized through the techniques of the present invention. Other embodiments and aspects of the invention are described in detail herein and are considered a part of the claimed invention.

#### BRIEF DESCRIPTION OF DRAWINGS

[0006] The foregoing and objects, features, and advantages of one or more aspects of the invention are apparent from the following detailed description taken in conjunction with the accompanying drawings in which:

[0007] FIG 1 depicts one example of an aspect of a computing environment used to execute one or more aspects of an embodiment of the present invention;

[0008] FIG 2 depicts one embodiment of a single processor computing environment to incorporate and use one or more aspects of the present invention;

[0009] FIG 3 depicts one embodiment of a computer program product incorporating one or more aspects of the present invention;

[0010] FIG 4 depicts a workflow of an embodiment of the present invention;

[0011] FIG 5-20 depict examples of an exemplary graphical user interface (GUI) produced by an aspect of the present invention;

[0012] FIG 21 depicts a workflow of an embodiment of the present invention;

[0013] FIG 22 depicts a model related to an aspect of an embodiment of the present invention; and

[0014] FIG 23 depicts an example of a two compartment model that is utilized when evaluating meropenem.

## DETAILED DESCRIPTION OF THE INVENTION

[0015] Aspects of the present invention and certain features, advantages, and details thereof, are explained more fully below with reference to the non-limiting examples illustrated in the accompanying drawings. Descriptions of well-known materials, fabrication tools, processing techniques, etc., are omitted so as not to unnecessarily obscure the invention in detail. It should be understood, however, that the detailed description and the specific examples, while indicating aspects of the invention, are given by way of illustration only, and not by way of limitation. Various substitutions, modifications, additions, and/or arrangements, within the spirit and/or scope of the underlying inventive concepts will be apparent to those skilled in the art from this disclosure.

[0016] Appropriate treatment with anti-infective therapies, including but not limited to, antibiotics, antibacterial, antifungals, antivirals, and/or antimicrobials involves many factors that cannot be controlled by clinicians. For example, factors such as inter-patient variability in drug exposure, the minimum inhibitory concentration (MIC) of the infecting pathogen, and the patient's clinical status, can affect the probability of attaining a PK-PD target associated with efficacy for a drug regimen. The MIC refers to the minimum concentration of a drug therapy that will inhibit the growth of the isolated pathogen. Despite these uncertainties, embodiments of the present method and system enable a clinician (user) to obtain estimates of the probability of attaining PK-PD targets associated with efficacy in the context of predefined factors based upon the selection and application of pharmacokinetic models and simulation by program code executed on at least one processor of a computer system. In order to describe the concentration of drug over time in the body, pharmacokinetic models can be used to describe the disposition of a drug including where and how fast the drug is transferring throughout the body.

[0017] In an embodiment of the present invention, the predefined factors that enable the present technique to estimate probability of attaining a PK-PD target associated with efficacy outcome include, but are not limited to, factors that are within the control of the clinician and/or known to the clinician.

[0018] Embodiments of the present invention estimate anti-infective drug exposure for a given patient using data including, but not limited to, infection(s) acquired by the given patient, pathogen(s) isolated from the given patient, and demographic information describing the given patient, including but not limited to, the patient's creatinine clearance, weight, and height. The present invention obtains inputs and identifies and applies relevant pharmacokinetic models and/or tabular outputs to create a listing of potentially useful drug therapies. In embodiments of the present invention, results of the present technique include different options for antibiotic dosing regimens (which consider drug, dose and the dosing interval) for a given patient including drug, dose, and the dosing interval and a comparison of these different options with a ranking based on the probability of attaining PK-PD targets associated with efficacy. An embodiment of the present invention is designed to provide information rather than recommendations for individual patients. The information provided, including but not limited to, the options, may be utilized for decision support and not as a final recommendation without clinical judgment (*i.e.*, without the consideration of other factors such as adverse events).

[0019] In an embodiment of the present invention, upon obtaining information related to the given person, for each drug therapy considered, the invention indexes drug exposure to a measure of susceptibility, the MIC, which represents the concentration of drug that inhibits the growth of the pathogen being considered. The MIC can either be a known value, a distribution of values, or the value of defining susceptibility based on *in vitro* susceptibility test interpretive criteria. In this embodiment, the indexed drug exposure for each drug, which is referred to as a PK-PD index, can take several forms, including but not limited to the following: the ratio of the area under the concentration time-curve over a period of time (e.g., 24 hours) to the MIC (AUC:MIC ratio), the percent of the dosing interval that the drug concentration remains above the MIC (% time above MIC), and the ratio of the maximal drug concentration in the dosing interval to the MIC (C<sub>max</sub>:MIC ratio). The PK-PD index for a given drug and dosing regimen is compared to that required for efficacy, based on pre-clinical or clinical infection exposure-response models. Using one or more equations and/or models that account for sources of variability, the probability of attaining a PK-PD index relative to those associated with efficacy based on pre-clinical or clinical infection exposure-response models (*i.e.*, PK-PD

targets associated with efficacy) for each listed antibiotic and dose regimen is then determined for that patient.

[0020] In an embodiment of the present invention, the software can determine a ranking for each evaluated drug therapy based on the probability of attaining a PK-PD target associated with efficacy relative to other identified relevant therapies.

[0021] In an embodiment of the present invention, collected information and resulting probabilities are stored for future access, for example, in a data store or a database that is accessible to program code executing on a processor in an embodiment of the present invention.

[0022] In a further embodiment of the present invention, a user can utilize the software to track results after an option is relayed to a given individual. In an embodiment of the present invention, the program code utilizes the patient information and the relevant data to estimate the probability of attaining a PK-PD target associated with efficacy for a given drug regimen. In order to provide the user with a full view of treatment options, in an embodiment of the present invention, in addition to evaluating the anti-infective used by the program code, the program code also identifies additional anti-infectives for consideration based on the patient information and/or relevant data. The one or more anti-infective obtained by the program code from the user as well as the additional anti-infectives may both be considered by the program code when estimating the probability of attaining a PK-PD target associated with efficacy for a given patient.

[0023] FIG 1 is a computer system 100 configured to perform at least one aspect of an embodiment of the present invention. In the embodiment of FIG 1, software 10 is executed by at least one processor on a computer, termed a base computer 12 in FIG 1 for clarity. The terms software, program code, computer program code, code, computer program product, and executable instructions, are used interchangeably throughout this application.

[0024] The software comprises code that is accessible to the processor and executable by at least one processor of the computer 12. The software can be stored on a memory on the physical computer 12, and/or in a memory and/or on removable media accessible to the computer 12 via a network connection, including but not

limited to, a wireless and/or wireless network, utilizing a protocol known to one of skill in the art. The computer may also be configured to act as a web server, which may be capable of running the software and hosting and/or interacting with the database 14.

[0025] The base computer 12, as well as any other computer described in the present specification can include personal computers, servers, smart phones, mobile devices, laptops, desktops, and/or any means of personal or corporate computing device capable of executing the software 10 or portions of the software 10, or communicating with a computer executing the software 10 over a wireless or hard wired network.

[0026] In the embodiment of FIG 1, the base computer is connected to a computer network 16, including but not limited to private and publicly accessible wired and wireless networks, and the Internet. In this embodiment, one or more computers, termed auxiliary computers 18a-18c are communicatively connected to the computer 12 via a computer network 16, including but not limited to, the Internet. The auxiliary computer 18a-18c receive data from the computer 12, via, for example, the web application server on the computer 12 and the auxiliary computers 18a-18c can render (for viewing) determinations regarding the probability of attaining a PK-PD target associated with efficacy for various antibiotics for the treatment of given patients based on data describing the given patient obtained at the base computer 12 and/or stored on the database 14 accessible to a processing resource on the base computer 12, including but not limited to, demographic information, and/or clinical laboratory data. The base computer can obtain data from the auxiliary computers 18a-18c, including but not limited to, the aforementioned descriptive data regarding the given patient for whom an antibiotic option is sought. As understood by one of skill in the art, the program code in various embodiment of the present invention can be stored on a memory resource and/or executed on one or more of the base computer 12 and/or the auxiliary computers 18a-18c.

[0027] The base computer 12 in the embodiment of FIG 1 includes a database 14. Additional embodiments of the present invention utilize databases and other memory devices in different physical locations that are remotely accessible to the base computer 12 executing the software 10. In the embodiment of FIG 1, the database 14

stores data including, but not limited to, population pharmacokinetic model-based equations and/or tabular outputs for a listing of potentially useful antibiotics that can be used to treat selected infectious diseases, information relating to various antibiotics and patients to whom they were offered by the present method, and/or the results of options returned by embodiments of the present invention.

[0028] FIG. 2 illustrates a block diagram of a resource 200, like base computer 12 and/or auxiliary computers 18a-18c, in computer system 100, which is part of the technical architecture of certain embodiments of the technique. The resource 200 may include a circuitry 202 that may in certain embodiments include a microprocessor 204. The computer system 200 may also include a memory 206 (e.g., a volatile memory device), and storage 208. The storage 208 may include a non-volatile memory device (e.g., EEPROM, ROM, PROM, RAM, DRAM, SRAM, flash, firmware, programmable logic, etc.), magnetic disk drive, optical disk drive, tape drive, etc. The storage 208 may comprise an internal storage device, an attached storage device and/or a network accessible storage device. The system 200 may include a program logic 210 including code 212 that may be loaded into the memory 206 and executed by the microprocessor 204 or circuitry 202.

[0029] In certain embodiments, the program logic 210 including code 212 may be stored in the storage 208, or memory 206. In certain other embodiments, the program logic 210 may be implemented in the circuitry 202. Therefore, while FIG. 2 shows the program logic 210 separately from the other elements, the program logic 210 may be implemented in the memory 206 and/or the circuitry 202.

[0030] Using the processing resources of a resource 200 to execute software, computer-readable code or instructions, does not limit where this code can be stored. The terms program logic, code, and software are used interchangeably throughout this application.

[0031] Referring to FIG. 3, in one example, a computer program product 300 includes, for instance, one or more non-transitory computer readable storage media 302 to store computer readable program code means or logic 304 thereon to provide and facilitate one or more aspects of the technique.

[0032] As will be appreciated by one skilled in the art, aspects of the technique may be embodied as a system, method or computer program product. Accordingly, aspects of the technique may take the form of an entirely hardware embodiment, an entirely software embodiment (including firmware, resident software, micro-code, etc.) or an embodiment combining software and hardware aspects that may all generally be referred to herein as a "circuit," "module" or "system." Furthermore, aspects of the technique may take the form of a computer program product embodied in one or more computer readable medium(s) having computer readable program code embodied thereon.

[0033] Any combination of one or more computer readable medium(s) may be utilized. The computer readable medium may be a computer readable signal medium or a computer readable storage medium. A computer readable signal medium may include a propagated data signal with computer readable program code embodied therein, for example, in baseband or as part of a carrier wave. Such a propagated signal may take any of a variety of forms, including, but not limited to, electro-magnetic, optical or any suitable combination thereof. A computer readable signal medium may be any computer readable medium that is not a computer readable storage medium and that can communicate, propagate, or transport a program for use by or in connection with an instruction execution system, apparatus or device.

[0034] A computer readable storage medium may be, for example, but not limited to, an electronic, magnetic, optical, electromagnetic, infrared or semiconductor system, apparatus, or device, or any suitable combination of the foregoing. More specific examples (a non-exhaustive list) of the computer readable storage medium include the following: an electrical connection having one or more wires, a portable computer diskette, a hard disk, a random access memory (RAM), a read-only memory (ROM), an erasable programmable read-only memory (EPROM or Flash memory), an optical fiber, a portable compact disc read-only memory (CD-ROM), an optical storage device, a magnetic storage device, or any suitable combination of the foregoing. In the context of this document, a computer readable storage medium may be any tangible medium that can contain or store a program for use by or in connection with an instruction execution system, apparatus, or device.

[0035] Program code embodied on a computer readable medium may be transmitted using an appropriate medium, including but not limited to wireless, wireline, optical fiber cable, RF, etc., or any suitable combination of the foregoing.

[0036] Computer program code for carrying out operations for aspects of the technique may be written in any combination of one or more programming languages, including an object oriented programming language, such as Java, Smalltalk, C++ or the like, and conventional procedural programming languages, such as the "C" programming language, assembler or similar programming languages. The program code may execute entirely on the user's computer, partly on the user's computer, as a stand-alone software package, partly on the user's computer and partly on a remote computer or entirely on the remote computer or server. In the latter scenario, the remote computer may be connected to the user's computer through any type of network, including a local area network (LAN) or a wide area network (WAN), or the connection may be made to an external computer (for example, through the Internet using an Internet Service Provider).

[0037] Aspects of the technique are described herein with reference to flowchart illustrations and/or block diagrams of methods, apparatus (systems) and computer program products according to embodiments of the invention. It will be understood that each block of the flowchart illustrations and/or block diagrams, and combinations of blocks in the flowchart illustrations and/or block diagrams, can be implemented by computer program instructions. These computer program instructions may be provided to a processor of a general purpose computer, special purpose computer, or other programmable data processing apparatus to produce a machine, such that the instructions, which execute via the processor of the computer or other programmable data processing apparatus, create means for implementing the functions/acts specified in the flowchart and/or block diagram block or blocks.

[0038] These computer program instructions may also be stored in a computer readable medium that can direct a computer, other programmable data processing apparatus, or other devices to function in a particular manner, such that the instructions stored in the computer readable medium produce an article of manufacture including instructions which implement the function/act specified in the flowchart and/or block diagram block or blocks.

[0039] The computer program instructions, also referred to as computer program code, may also be loaded onto a computer, other programmable data processing apparatus, or other devices to cause a series of operational steps to be performed on the computer, other programmable apparatus or other devices to produce a computer implemented process such that the instructions which execute on the computer or other programmable apparatus provide processes for implementing the functions/acts specified in the flowchart and/or block diagram block or blocks.

[0040] The flowchart and block diagrams in the figures illustrate the architecture, functionality, and operation of possible implementations of systems, methods and computer program products according to various embodiments of the technique. In this regard, each block in the flowchart or block diagrams may represent a module, segment, or portion of code, which comprises one or more executable instructions for implementing the specified logical function(s). It should also be noted that, in some alternative implementations, the functions noted in the block may occur out of the order noted in the figures. For example, two blocks shown in succession may, in fact, be executed substantially concurrently, or the blocks may sometimes be executed in the reverse order, depending upon the functionality involved. It will also be noted that each block of the block diagrams and/or flowchart illustration, and combinations of blocks in the block diagrams and/or flowchart illustration, can be implemented by special purpose hardware-based systems that perform the specified functions or acts, or combinations of special purpose hardware and computer instructions.

[0041] In addition to the above, one or more aspects of the technique may be provided, offered, deployed, managed, serviced, etc. by a service provider who offers management of customer environments. For instance, the service provider can create, maintain, support, etc. computer code and/or a computer infrastructure that performs one or more aspects of the technique for one or more customers. In return, the service provider may receive payment from the customer under a subscription and/or fee agreement, as examples. Additionally or alternatively, the service provider may receive payment from the sale of advertising content to one or more third parties.

[0042] In one aspect of the technique, an application may be deployed for performing one or more aspects of the technique. As one example, the deploying of

an application comprises providing computer infrastructure operable to perform one or more aspects of the technique.

[0043] As a further aspect of the technique, a computing infrastructure may be deployed comprising integrating computer readable code into a computing system, in which the code in combination with the computing system is capable of performing one or more aspects of the technique. As a further aspect of the technique, the system can operate in a peer to peer mode where certain system resources, including but not limited to, one or more databases, is/are shared, but the program code executable by one or more processors is loaded locally on each computer (workstation).

[0044] As yet a further aspect of the technique, a process for integrating computing infrastructure comprising integrating computer readable code into a computer system may be provided. The computer system comprises a computer readable medium, in which the computer medium comprises one or more aspects of the technique. The code in combination with the computer system is capable of performing one or more aspects of the technique.

[0045] Further, other types of computing environments can benefit from one or more aspects of the technique. As an example, an environment may include an emulator (*e.g.*, software or other emulation mechanisms), in which a particular architecture (including, for instance, instruction execution, architected functions, such as address translation, and architected registers) or a subset thereof is emulated (*e.g.*, on a native computer system having a processor and memory). In such an environment, one or more emulation functions of the emulator can implement one or more aspects of the technique, even though a computer executing the emulator may have a different architecture than the capabilities being emulated. As one example, in emulation mode, the specific instruction or operation being emulated is decoded, and an appropriate emulation function is built to implement the individual instruction or operation.

[0046] In an emulation environment, a host computer includes, for instance, a memory to store instructions and data; an instruction fetch unit to fetch instructions from memory and to optionally, provide local buffering for the fetched instruction; an instruction decode unit to receive the fetched instructions and to determine the type of

instructions that have been fetched; and an instruction execution unit to execute the instructions. Execution may include loading data into a register from memory; storing data back to memory from a register; or performing some type of arithmetic or logical operation, as determined by the decode unit. In one example, each unit is implemented in software. For instance, the operations being performed by the units are implemented as one or more subroutines within emulator software.

[0047] Further, a data processing system suitable for storing and/or executing program code is usable that includes at least one processor coupled directly or indirectly to memory elements through a system bus. The memory elements include, for instance, local memory employed during actual execution of the program code, bulk storage, and cache memory which provide temporary storage of at least some program code in order to reduce the number of times code must be retrieved from bulk storage during execution.

[0048] Input/Output or I/O devices (including, but not limited to, keyboards, displays, pointing devices, DASD, tape, CDs, DVDs, thumb drives and other memory media, etc.) can be coupled to the system either directly or through intervening I/O controllers. Network adapters may also be coupled to the system to enable the data processing system to become coupled to other data processing systems or remote printers or storage devices through intervening private or public networks. Modems, cable modems, and Ethernet cards are just a few of the available types of network adapters.

[0049] FIG 4 depicts a workflow 400 of aspects of an embodiment of the present technique. In order to estimate the anti-infective drug exposure for a given patient, program code executed by at least one processor on a computer resource, such as resource 200, obtains descriptive information about an infection (S410), including but not limited to, where the infection is located, and/or where the infection was acquired.

[0050] FIG 5 depicts an example of a graphical user interface 510 on a mobile device 500, which is a computer resource that can be an aspect of embodiments of the present invention. The screen depicted in FIG 5 is termed the “Infection” screen where a user, for example, a clinician, can select descriptive terms to assist the

program code in executing on a processor of this computer resource in obtaining further characteristics about the infection.

[0051] Returning to FIG 4, upon obtaining descriptive information about the infection, the program code generates and displays a listing of possible pathogens that are consistent with the descriptive information provided (S420). As seen to FIG 6, which depicts a GUI with an exemplary screen listing possible pathogens, the listing generated by the program code can include an indication of what is the most likely and/or possible pathogen, based on the description. In an embodiment of the present invention, the program code executed by the processor can make this determination by accessing data on a storage medium that is located either local to the computer resource or accessible via a communications connection.

[0052] Returning to FIG 4, the program code executed by a processor of the computer resource obtains data describing a pathogen (S430). As seen in FIG 7, a user of this embodiment of the present invention, the program code can obtain the pathogen when the user makes a selection in the GUI that is displayed by the program code listing possible pathogens.

[0053] Responsive to receiving the data describing a pathogen, the program code executed by a processor generates a list of drug therapies (S440), including but not limited to, antibiotics, that are options for treating the pathogen. The list generated by the program code executed by a processor can include a single result or a group of results, based upon the information obtained.

[0054] In an embodiment of the present invention, data related to drug therapies that may comprise the list created by the program code can be stored on a memory resource that is integral to the computer resource and/or accessible to the computer resource via a communications connection.

[0055] FIG 8 is an example of a list of drug therapies generated by program code in an embodiment of the present invention. In the example of FIG 8, a list of antibiotics was generated by the program code and displayed to the user. From this list of drug therapies related to the identified pathogen and/or infection, in an embodiment of the present invention, the user, such as a clinician, can select from the list one or more drug therapies for further evaluation in order to receive the probability of attaining the

PK-PD target associated with efficacy for the drug in treating a given patient. In an embodiment of the present invention, the drug therapies that are listed to a user by the program code comprise drug therapies that have known success in treating the pathogen obtained by the program code, *e.g.*, identified by the user through an input into the computer resource.

[0056] Returning to FIG 4, the program code obtains one or more of the drug therapies for further evaluation by the program code (S450). As aforementioned, the program code can receive the one or more drug therapies for further evaluation based upon a selection made by the user using an input device, such as a touch screen. FIG 9 in an example of a screen of a GUI, in an embodiment of the present invention, where a user has selected drug therapies, in this example, antibiotics, for further analysis by the program code. In an embodiment of the present invention, in addition to the program code listing drug therapies from which a user can select, a user can also enter one or more drug therapies for evaluation. The program code may retain the entered drug therapies and save the drug therapies and their relationship in treating a given pathogen, on a memory resource, for future use, including but not limited to one or more remote memory resource(s). In an embodiment of the present invention, the program code obtains a listing of potentially useful antibiotics that can be used to treat selected infectious diseases indicated by the infections and/or pathogens experienced by the given patient from a memory resource.

[0057] In a further embodiment of the present invention, the program code evaluates all the drug therapies provided rather than enable a user, or an automatic process, to limit the number of therapies further evaluated.

[0058] Returning to FIG. 4, the program code also obtains a minimum inhibitory concentration (MIC) value or distribution of MIC values to be utilized in evaluating the probability of attaining a PK-PD target associated with efficacy for a particular drug (S460). The user can select the type of MIC distribution that the program code will apply. The MIC is the lowest concentration of an antimicrobial that will inhibit the visible growth of a microorganism after overnight incubation. Because the MIC value relates to an *in vitro* measurement of the efficacy of a drug, the efficacy of the drug therapy, as related to a given patient, is not immediately apparent without

utilizing additional parameters and applying a relevant pharmacokinetic model, which is discussed later.

[0059] Depending upon the type of drug therapies being contemplated, the user may select a MIC distribution rather than a fixed MIC value. FIG 10 is an example of a GUI utilized in an embodiment of the present invention to display to a user select choices of MIC values. As susceptibility patterns and hence, likely MIC values may be influenced by the geographical location of a given patient, should a user select a distribution of MIC values based on surveillance data, including but not limited to, the SENTRY repository of data, such as SENTRY 2014), the user can be prompted to enter the location of the patient, as seen in FIG 11.

[0060] In an embodiment of the present invention, the computer resource can include a GPS that the program code utilizes to find the location of the user and therefore, apply the relevant MIC distribution. As seen in FIG 11, the program code displays a "Locate me" function. In this example, when a user selects this location function, the program code will request location information from the GPS and receive this information, which it will use to generate a user location, responsive to the request.

[0061] Returning to FIG. 4, as discussed earlier, demographic information related to the patient is also utilized by the program code determining the probability of attaining PK-PD targets associated with efficacy for known drug therapies. Thus, the program code obtains descriptive information relating to the given patient (S470). The descriptive information includes, but is not limited to, the weight of the patient and the creatinine clearance of the given patient.

[0062] In an embodiment of the present invention, the program code displays a list of descriptive information relating to existing patients, enabling the user to select a patient from this listing. The existing patient records may be retained on an accessible memory resource, such as a database. An example of a GUI where the program code renders a list of existing patients is displayed as FIG 12.

[0063] In an embodiment of the present invention, program code executed by a processor can obtain user information from user entry. For example, a user can enter patient information related to a new patient. This option is also visible in FIG 12 and

if selected, in an embodiment of the present invention, the program code produces a GUI where the user can enter new patient information, as seen in FIGs 13A and 13B. As aforementioned, among the parameters requested in the GUI and therefore, received by the program code, are the patient's weight and serum creatinine. As seen in FIGs 13A and 13B, in compliance with HIPAA regulations, the GUI where a user can enter patient information can be configured to warn a user not to enter any patient-identifiable information. Additionally, in an embodiment of the present invention, the program code does not obtain and/or retain private information in violation of HIPAA.

[0064] Once the program code has obtained the drug therapy being considered, including descriptive factors that may include, but are not limited to, the dosage, duration of infusion, and/or dosing interval, the MIC or the MIC distribution, and the aforementioned patient characteristics, the program code determines the probability of attaining the PK-PD target associated with efficacy for the selected drug therapy and/or therapies. In an embodiment of the present invention, the program code executed by a processor displays a summary screen to a user that includes the data obtained that the program code will utilize to determine PK-PD target attainment. FIG 14 is an example of a summary screen.

[0065] Referring to FIG 14, the summary screen lists the infection, the pathogen, the selected drug therapies, which, in this example, are antibiotics, and the selection made for MIC. The summary screen also lists descriptive information about the patient, in this example, the gender, age, weight, height, serum creatinine, and category of hepatic function. The program code will vary the parameters utilized in determining the probability of attaining a PK-PD target associated with efficacy for each therapy, based upon that therapy. For example, while the height of the patient may assist in a determination for a given drug therapy, that parameter may not be used by the program code in determining the probability of attaining a PK-PD target associated with efficacy for a different drug. Thus, returning to FIG 4, based upon each drug therapy selected, the program code selects a pharmacokinetic model to apply to determine an exposure and the probability of attaining a PK-PD target associated with efficacy for that drug therapy, which in an embodiment of the present invention, is expressed as a percent probability (S480). The program code utilizes at

least one pharmacokinetic model in determining the probability of attaining a PK-PD target associated with efficacy for a given drug therapy for a given patient. Thus, upon selecting a pharmacokinetic model, the program code applies the model in order to determine the probability of attaining a PK-PD target associated with efficacy for that particular drug given a specific target (S490).

[0066] The pharmacokinetic models associated with different drug therapies use mathematical representations of parts of the body to describe the time-course of drug concentrations in the body. To describe the parts of the body affecting the time-course of drug concentrations, the body of the patient can be understood as containing compartments. The models account for  $n$  number of compartments. Some models utilize three compartments. Taking the drug therapy, meropenem as an example, its pharmacokinetics can be described using two compartments. The two compartments represent blood and tissue. This two compartment type of pharmacokinetic model is applied during and after infusion.

[0067] In a two-compartment pharmacokinetic model discussed later in this document,  $V_c$  stands for "volume of the central compartment" which is usually blood. Thus, when a drug is infused ( $K_0$ ), it will be input into this compartment. The second compartment,  $V_p$ , stands for "peripheral compartment" which approximates the tissue. The transfer rate of drug between these two compartments is called "distributional clearance" ( $CL_d$ ). In the central compartment, drug will be eliminated (by routes such as renal excretion or metabolism) and this is considered an output and is termed "total clearance" ( $CL_t$ ). These parameters can be calculated if equations are known for a given drug therapy, and, as aforementioned, for most drug therapies, the patient weight, and creatinine clearance for a given patient are also known.

[0068] Returning to FIG 14, when utilizing the GUI of an embodiment of the present invention, the user can visually verify that the information on the summary screen is correct and submit this information to the program code for determination of the probability of attaining a PK-PD target associated with efficacy for each selected drug therapy, as discussed in reference to FIG 4.

[0069] In an embodiment of the present invention, once the program code has determined a probability of attaining a PK-PD target associated with efficacy for each

selected drug therapy and/or drug therapies that were not selected by the user, the program code ranks the results in order of probabilities for the drug therapies selected for consideration and separately for those obtained for considered by the program code (S491). FIG 15 is an example of a screen of a GUI utilized in an embodiment of the present invention to display the determined probabilities of PK-PD target attainment, and rank the drug therapies by these probabilities.

[0070] After providing a user with the probability of attaining a PK-PD target associated with efficacy for drug therapies considered, in an embodiment of the present invention, the program code can obtain the selection of the user of the drug therapy he or she intends to administer to the given patient (S495). In an embodiment of the present invention, the program code retains the selection on a memory device accessible to the processor. In an embodiment of the present invention, the program code can generate a GUI that displays individual results for the probability of attaining a PK-PD target associated with efficacy for various drug therapies from a listing screen, such as FIG 15. FIG 16 is an example of this type of detail screen, in this case, for the drug therapy Tedizolid. The probability of attaining the PK-PD target associated with efficacy for the drug therapy is presented in the context of the infection and/or pathogen obtained by the program code upon entry of information by a user.

[0071] In an embodiment of the present invention, the user can track the actual efficacy of the drug therapy selected, for example, to compare and contrast the expected outcome with the actual outcome. In FIG 17, once the user has selected the drug therapy from the drug therapies returned as options, the user can select whether he or she would like to be prompted to follow up with the patient. Should the user opt to follow up, in an embodiment of the present invention, the program code will display a reminder to the user to follow up regarding a given patient. FIG 18 is an example of a possible display for this follow up activity and additionally may collect information regarding efficacy, including but not limited to, requesting that a user enter information and/or importing information from an external data repository. In an embodiment of the present invention, the reminder generated by the program code can be audible and/or visual.

[0072] Returning to FIG. 4, in an embodiment of the present invention where the program code obtains a follow up request, the program code will prompt the user for follow up in accordance with this request (S496).

[0073] FIG 19 is an example of a Follow-up screen that can be utilized in order to note the efficacy of the drug therapy when administered to the given patient. FIGs 19-20 represent different types of questions/data that can be asked/collected by the program code in order to track the success of the selected treatment.

[0074] As aforementioned when discussing FIG 4, the program code selects a pharmacokinetic model to apply to determine the probability of attaining a PK-PD target associated with efficacy for a given drug therapy. The following sections provide examples of the models that can be applied in various embodiments of the present invention and how these models can be applied by the program code. FIG 21 detail various determinations made by the program code in selecting and applying a pharmacokinetic model to a given drug therapy.

[0075] In an aspect of the present invention, in order to select the pharmacokinetic model, the program code first determines which PK-PD index classification best describes the efficacy of the drug. While there are more than two possible categories for this classification, as one example, FIG 21 provides an example based on only two categories (S2110). In the first class, the probability of attaining the PK-PD target associated with efficacy for a drug therapy is determined at least in part, based upon the total drug exposure in a 24 hour period, wherein the AUC:MIC ratio is at least part of the determination (S2120a). In the second class, the % time above MIC is calculated and comprises at least a portion of the determination (S2120b). Despite the categorization of drugs into these two distinct classes by the program code, the model applied by the program code will differ between drugs. Depending upon a drug therapy selected, the program code may apply a customized model, including varying the parameters requested from a user, to ultimately determine the probabilities displayed. However, in embodiments of the present invention, the class to which the drug belongs directs the type of model utilized by the program code.

[0076] An example of one drug therapy that would be classified in the first category is ciprofloxacin. As aforementioned, the program code selects and applies the models

based upon the drug therapy itself. However, the patient characteristics and MIC obtained by the program code affect the resulting prediction of PK-PD target attainment.

[0077] In the equations below, an estimated probability of attaining a PK-PD target associated with efficacy for ciprofloxacin is determined based upon parameters related to ciprofloxacin and obtained by the program code in the manner described in FIG 4. The parameters obtained by the program include, but are not limited to, the drug therapy and dosage, which in the example below, the drug therapy is ciprofloxacin which is given every 8 hours intravenously. The patient characteristics are:

[0078] 1) Creatinine clearance (CL<sub>cr</sub>): 63 mL/min; and

[0079] 2) Weight (WT):.

[0080] The MIC in the example below is 1 mg/L

[0081] Utilizing parameters, specific to ciprofloxacin, the program code determines the area under the curve over 24 hours ( $AUC_{24}$ ). Equation 1 is an example of an Equation that the program code can utilize to make this determination. In the Equation 2, below, the  $AUC_{24}$  is used to find the total clearance (CL<sub>t</sub>).

$$AUC_{24} = \frac{\text{Daily Dose}}{CL_t} \quad (\text{Equation 1})$$

$$CL_t = (0.00145 \times CL_{cr} + 0.167) \times WT \quad (\text{Equation 2})$$

[0082] By applying the parameters discussed, the following calculations can be made:

$$\begin{aligned} \text{Daily dose} &= 400 \text{ mg}/8\text{hr} \times 24 \text{ hr} = 1200 \text{ mg} \\ CL_t &= (0.00145 \times 63 + 0.167) \times 70 = 18.1 \text{ L/hr} \\ AUC_{24} &= 1200/18.1 = 66.4 \text{ mg/L} \times \text{hr} \end{aligned}$$

$$AUC:MIC \text{ ratio} = \frac{AUC_{24}}{MIC} = \frac{66.4}{1} = 66.4$$

[0083] Once the AUC:MIC ratio is calculated, it is compared to the threshold for AUC:MIC ratio associated with efficacy (i.e., the PK-PD target). If it is above the PK-PD target, a patient is more likely to have a successful response to therapy; if it is below, the patient is less likely. A point estimate for probability of PK-PD target attainment will be determined as a function of the AUC:MIC ratio. The variability about this estimate is also determined by the program code. Thus, by obtaining parameters from a user and/or a memory resource, determining the relevant model, applying the model and using simulation, and returning a result to a user.

[0084] Returning to FIG 21, if the drug therapy being evaluated by the program code is in the second class, the program code calculates the % time above the MIC, which comprises at least a portion of the determination (S2120b). As discussed earlier, in embodiments of the present invention, in order to predict the probability of attaining the PK-PD target associated with efficacy for a given drug therapy, the pharmacokinetic model applied depends upon the actual drug, so the program code determined what model to apply based upon the drug therapy. Meropenem is an example of a drug therapy that is a member of this class and is used as an example in explaining an example of a pharmacokinetic model applied to members of this PK-PD classification.

[0085] FIG 22 is an example of the application of a pharmacokinetic model to determine the efficacy of the drug therapy for a given patient. Referring to FIG 22, as explained earlier, the program code obtains patient characteristics, a MIC, and the drug therapy and dose parameters. The program code uses these parameters to compute the % time above MIC. To make this determination, the program code computes the  $K_{cp}$ ,  $K_{pc}$ , and  $K_{el}$  values, the Alpha and Beta, the A and B and then, and uses these values to find the concentration during infusion, the concentration after infusion, and then applies these values to calculate a final efficacy percentage for the drug for the given patient. The derivation of these individual values is discussed below. The variables utilized in the present example are defined as follows:  $K_{cp}$  is the rate constant for flow from central to peripheral;  $K_{pc}$  is rate constant for flow from peripheral to central; Alpha is the rate constant for the first phase of drug elimination; Beta is the rate constant for the second phase of drug elimination; A is

the concentration in the alpha phase at time 0; and B is the concentration in the beta phase at time 0.

[0086] FIG 23 shows an example of a two compartment model that is utilized when evaluating meropenem. In the figure, the compartment with Vc stands for "volume of the central compartment" which is usually blood. Thus, when meropenem is infused (arrow with Ko), it will be inputted into this compartment. The second compartment, Vp, "peripheral compartment," is for tissue. The transfer rate of drug between these two compartments is called "distributional clearance" (CLd). In the central compartment, drug will be eliminated (by routes such as renal excretion or metabolism) and this is considered an output (arrow going out to nowhere) and is termed "total clearance" (CLt).

[0087] Using a steady state model and the two-compartment model for and the drug meropenem, the Equation 3 and Equation 4 can be applied.

$$fC(t) = f_{up} \times K_0 \left[ \frac{A}{\alpha} \left( 1 - e^{-\alpha t} + e^{-\alpha t} \frac{(1 - e^{-\alpha T_{inf}}) e^{-\alpha(t-T_{inf})}}{1 - e^{-\alpha T}} \right) + \frac{B}{\beta} \left( 1 - e^{-\beta t} + e^{-\beta t} \frac{(1 - e^{-\beta T_{inf}}) e^{-\beta(t-T_{inf})}}{1 - e^{-\beta T}} \right) \right]$$

Equation 3

$$fC(t) = f_{up} \times K_0 \left[ \frac{A}{\alpha} \left( \frac{(1 - e^{-\alpha T_{inf}}) e^{-\alpha(t-T_{inf})}}{1 - e^{-\alpha T}} \right) + \frac{B}{\beta} \left( \frac{(1 - e^{-\beta T_{inf}}) e^{-\beta(t-T_{inf})}}{1 - e^{-\beta T}} \right) \right]$$

Equation 4

[0088] Table 1 below includes the parameters utilized by the above equations.

|   |                             |  |  |
|---|-----------------------------|--|--|
| $A = \frac{1}{V_c} \frac{\alpha - K_{pc}}{\alpha - \beta}$  |                             | $B = \frac{1}{V_c} \frac{\beta - K_{pc}}{\beta - \alpha}$  |  |
| $\alpha = \frac{1}{2} [(K_{cp} + K_{pc} + K_{el}) + \sqrt{(K_{cp} + K_{pc} + K_{el})^2 - 4(K_{pc})(K_{el})}]$ |                             | $\beta = \frac{1}{2} [(K_{cp} + K_{pc} + K_{el}) - \sqrt{(K_{cp} + K_{pc} + K_{el})^2 - 4(K_{pc})(K_{el})}]$ |  |
| $K_{cp} = \frac{CL_d}{V_c}$   | $K_{pc} = \frac{CL_d}{V_p}$ | $K_{el} = \frac{CL_t}{V_c}$  |  |

|  |  |  |
|--|--|--|
|  |  |  |
|--|--|--|

TABLE 1

[0089] Below are values that can be utilized in the present invention for meropenem. In an embodiment of the present invention, the values can be retained on a memory resource and identified and utilized by the program code upon the program code categorizing the drug by the PK-PD index and identifying the appropriate model.

[0090] For meropenem:

[0091]  $V_c \text{ (Liters)} = 10.8 \times (\text{WT}/70)$

[0092]  $V_p \text{ (Liters)} = 12.6 \times (\text{WT}/70)$

[0093]  $CL_d \text{ (Liters/hour)} = 18.6 \times (\text{WT}/70)$

[0094]  $CL_t \text{ (Liters/hour)} = (10.2 + 2.08 \times CL_{cr}) \times (\text{WT}/70) \times 0.06$

[0095]  $\text{fraction unbound (fup)} = 0.98$

[0096] The variables utilized in the present example are defined as follows:  $K_{cp}$  is the rate constant for flow from central to peripheral;  $K_{pc}$  is the rate constant for flow from peripheral to central;  $\alpha$  is the rate constant for the first phase of drug elimination;  $\beta$  is the rate constant for the second phase of drug elimination;  $A$  is the concentration in the alpha phase at time 0; and  $B$  is the concentration in the beta phase at time 0.

[0097] An embodiment of the present invention can obtain the following drug and dose information:  $Dose = 2000$  milligrams; Duration of infusion ( $T_{inf}$ ) = 3 hours;  $K_0 = Dose/T_{inf} = 2000 \text{ mg}/3 \text{ hr}$ ; Dosing interval ( $\tau$ ) = 8 hours. This embodiment can also obtain the following patient characteristics: Creatinine clearance ( $CL_{cr}$ ) = 63.4 mL/min; Weight ( $WT$ ) = 86 kg. The present invention also obtains the following MIC:  $MIC = 8 \text{ mg/L}$ . Utilizing these values, the program code can determine  $K_{cp}$ ,  $K_{pc}$ , and  $K_{el}$  values, the  $\alpha$  and  $\beta$ , the  $A$  and  $B$  and then, and uses these values to find the concentration during infusion, the concentration after infusion, and then applies these values to calculate the probability of attaining the PK-PD target associated with efficacy for the drug for the given patient. In this example, the

program code returns the value of 99% for the probability of attaining the PK-PD target associated with efficacy for this drug with these parameters.

[0098] The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. As used herein, the singular forms "a", "an" and "the" are intended to include the plural forms as well, unless the context clearly indicates otherwise. It will be further understood that the terms "comprises" and/or "comprising", when used in this specification, specify the presence of stated features, integers, steps, operations, elements, and/or components, but do not preclude the presence or addition of one or more other features, integers, steps, operations, elements, components and/or groups thereof.

[0099] The corresponding structures, materials, acts, and equivalents of all means or step plus function elements in the descriptions below, if any, are intended to include any structure, material, or act for performing the function in combination with other elements as specifically noted. The description of the technique has been presented for purposes of illustration and description, but is not intended to be exhaustive or limited to the invention in the form disclosed. Many modifications and variations will be apparent to those of ordinary skill in the art without departing from the scope and spirit of the invention. The embodiment was chosen and described in order to best explain the principles of the invention and the practical application, and to enable others of ordinary skill in the art to understand the invention for various embodiments with various modifications as are suited to the particular use contemplated.

## CLAIMS

1. A method for determining a probability of attaining a PK-PD target associated with efficacy for a patient comprising:

obtaining, by a processor, information identifying an infection;

based on the information, generating and displaying, by the processor, a list comprising one or more pathogens consistent with the information;

obtaining, by the processor, a first indication designating at least one pathogen from the list comprising one or more pathogens;

based on at the obtaining of the least one pathogen, generating, by the processor, a list comprising one or more drug therapies utilized to treat the at least one pathogen;

obtaining, descriptive information relating to a patient;

based on the one or more drug therapies, selecting a pharmacokinetic model; and

applying, by the processor, the pharmacokinetic model and utilizing the information relating to the patient to determine, for each of the one or more drug therapies, a probability of attaining a PK-PD target associated with efficacy for the patient with the infection.

2. The method of claim 1, further comprising:

displaying, by the processor, the probability of attaining a PK-PD target associated with efficacy for the patient with the infection for each of the one or more drug therapies in order of efficacy.

3. The method of claim 1, further comprising:

obtaining, by the processor, a second indication designating at least one drug therapy from the list comprising one or more drug, wherein the each of the one or more drug therapies utilized in the selecting and the applying is limited to the at least one drug therapy comprising the second indication.

4. The method of claim 1, wherein the selecting comprises:

for each of the one or more drug therapies, determining a class for a PK-PD index;

based on determining that a drug therapy of the one or more drug therapies is in a first class, selecting a pharmacokinetic model, wherein applying the pharmacokinetic model comprises evaluating total drug exposure in a 24 hour period, for the drug therapy, to determine the probability of attaining a PK-PD target associated with efficacy for the patient with the infection; and

based on determining that a drug therapy of the one or more drug therapies is in a second class, selecting a pharmacokinetic model, wherein applying the pharmacokinetic model comprises evaluating % time above MIC, for the drug therapy, to determine the probability of attaining a PK-PD target associated with efficacy for the patient with the infection.

5. The method of claim 2, further comprising:

responsive to the displaying, obtaining, by the processor, a third indication comprising designation of a drug therapy form the one or more drug therapies displayed; and

retaining, by the processor, the designation on a memory device.

6. The method of claim 5, further comprising:

displaying, by the processor, a follow up option; and

responsive to obtaining a positive response to the follow up option, presenting a reminder to follow up with the patient on a graphical user interface.

7. A computer system for determining a probability of attaining a PK-PD target associated with efficacy for a patient, the computer system comprising:

a memory; and

a processor in communications with the memory, wherein the computer system is configured to perform a method, the method comprising: obtaining, by a processor, information identifying an infection;

based on the information, generating and displaying, by the processor, a list comprising one or more pathogens consistent with the information;

obtaining, by the processor, a first indication designating at least one pathogen from the list comprising one or more pathogens;

based on at the obtaining of the least one pathogen, generating, by the processor, a list comprising one or more drug therapies utilized to treat the at least one pathogen;

obtaining, descriptive information relating to a patient;

based on the one or more drug therapies, selecting a pharmacokinetic model; and

applying, by the processor, the pharmacokinetic model and utilizing the information relating to the patient to determine, for each of the one or more drug therapies, a probability of a attaining a PK-PD target associated with efficacy for the patient with the infection.

8. The computer system of claim 7, the method further comprising:

displaying, by the processor, the probability of attaining a PK-PD target associated with efficacy for the patient with the infection for each of the one or more drug therapies in order of probability of PK-PD target attainment.

9. The computer system of claim 7, the method further comprising:  
obtaining, by the processor, a second indication designating at least one drug therapy from the list comprising one or more drug, wherein the each of the one or more drug therapies utilized in the selecting and the applying is limited to the at least one drug therapy comprising the second indication.

10. The computer system of claim 7, wherein the selecting comprises:

for each of the one or more drug therapies, determining a class;

based on determining that a drug therapy of the one or more drug therapies is in a first class, selecting a pharmacokinetic model, wherein applying the pharmacokinetic model comprises evaluating total drug exposure in a 24 hour period, for the drug therapy, to determine the probability of attaining a PK-PD target associated with efficacy for the patient with the infection; and

based on determining that a drug therapy of the one or more drug therapies is in a second class, selecting a pharmacokinetic model, wherein applying the pharmacokinetic model comprises evaluating % time above MIC, for the drug therapy, to determine the probability of attaining a PK-PD target associated with efficacy for the patient with the infection.

11. The computer system of claim 8, the method further comprising:

responsive to the displaying, obtaining, by the processor, a third indication comprising designation of a drug therapy for the one or more drug therapies displayed; and

retaining, by the processor, the designation on a memory device.

12. The computer system of claim 11, the method further comprising:  
  
displaying, by the processor, a follow up option; and  
  
responsive to obtaining a positive response to the follow up option,  
displaying a reminder to follow up with the patient on a graphical user  
interface.
13. The computer system of claim 12, wherein the graphical user interface  
is on a mobile device.

14. A computer program product for determining a probability of attaining a PK-PD target associated with efficacy for a patient, the computer program product comprising:

a computer readable storage medium readable by a processing circuit and storing instructions for execution by the processing circuit for performing a method comprising:

obtaining, by a processor, information identifying an infection;

based on the information, generating and displaying, by the processor, a list comprising one or more pathogens consistent with the information;

obtaining, by the processor, a first indication designating at least one pathogen from the list comprising one or more pathogens;

based on at the obtaining of the least one pathogen, generating, by the processor, a list comprising one or more drug therapies utilized to treat the at least one pathogen;

obtaining, descriptive information relating to a patient;

based on the one or more drug therapies, selecting a pharmacokinetic model; and

applying, by the processor, the pharmacokinetic model and utilizing the information relating to the patient to determine, for each of the one or more drug therapies, a probability of attaining a PK-PD target associated with efficacy for the patient with the infection.

15. The computer program product of claim 14, the method further comprising:

displaying, by the processor, the probability of attaining a PK-PD target associated with efficacy for the patient with the infection for each of the one or more drug therapies in order of efficacy.

16. The computer program product of claim 14, the method further comprising:

obtaining, by the processor, a second indication designating at least one drug therapy from the list comprising one or more drug, wherein the each of the one or more drug therapies utilized in the selecting and the applying is limited to the at least one drug therapy comprising the second indication.

17. The computer program product of claim 14, wherein the selecting comprises:

for each of the one or more drug therapies, determining a class;

based on determining that a drug therapy of the one or more drug therapies is in a first class, selecting a pharmacokinetic model, wherein applying the pharmacokinetic model comprises evaluating total drug exposure in a 24 hour period, for the drug therapy, to determine the probability of attaining a PK-PD target associated with efficacy for the patient with the infection; and

based on determining that a drug therapy of the one or more drug therapies is in a second class, selecting a pharmacokinetic model, wherein applying the pharmacokinetic model comprises evaluating % time above MIC for the drug therapy to determine the probability of attaining a PK-PD target associated with efficacy for the patient with the infection.

18. The computer program product of claim 15, the method further comprising:

responsive to the displaying, obtaining, by the processor, a third indication comprising designation of a drug therapy for the one or more drug therapies displayed; and

retaining, by the processor, the designation on a memory device.

19. The computer program product of claim 18, the method further comprising:

displaying, by the processor, a follow up option; and

responsive to obtaining a positive response to the follow up option, generating a notification to follow up with the patient.

20. The computer program product of claim 15, where the probability of a positive outcome is displayed as a percentage value.





FIG 1

FIG 2



COMPUTER  
PROGRAM  
PRODUCT  
300




FIG 3




FIG 4




FIG 5




FIG 6



FIG 7



FIG 8



FIG 9



FIG 10




FIG 11




FIG 12




FIG 13A




FIG 13B




FIG 14




FIG 15




FIG 16




FIG 17




FIG 18




FIG 19




FIG 20

2100







FIG 21



Compute time above MIC




Result: Target Attainment  
 (as a single percentage value)

FIG 22

# FIG 23

## Example drug: Meropenem

Two-compartmental model:



Equations for intermittent infusion at steady state using two-compartmental model:

- During infusion: where  $0 \leq t \leq T_{inf}$

○  $fC(t) =$

$$f_{up} \times K_0 \left[ \frac{A}{\alpha} \left( 1 - e^{-\alpha t} + e^{-\alpha \tau} \frac{(1 - e^{-\alpha T_{inf}}) e^{-\alpha(t - T_{inf})}}{1 - e^{-\alpha \tau}} \right) + \frac{B}{\beta} \left( 1 - e^{-\beta t} + e^{-\beta \tau} \frac{(1 - e^{-\beta T_{inf}}) e^{-\beta(t - T_{inf})}}{1 - e^{-\beta \tau}} \right) \right]$$

- After infusion: where  $T_{inf} < t < \tau$

○  $fC(t) = f_{up} \times K_0 \left[ \frac{A}{\alpha} \left( \frac{(1 - e^{-\alpha T_{inf}}) e^{-\alpha(t - T_{inf})}}{1 - e^{-\alpha \tau}} \right) + \frac{B}{\beta} \left( \frac{(1 - e^{-\beta T_{inf}}) e^{-\beta(t - T_{inf})}}{1 - e^{-\beta \tau}} \right) \right]$

The parameters are:

|  |   |
|--|---|
| $A = \frac{1}{V_c} \frac{\alpha - K_{pc}}{\alpha - \beta}$ | $B = \frac{1}{V_c} \frac{\beta - K_{pc}}{\beta - \alpha}$ |
|--|---|

FIG 23 (con)

|  |  |   |                           |
|--|--|---|---------------------------|
| $\alpha = \frac{1}{2} \left[ (K_{cp} + K_{pc} + K_{el}) + \sqrt{(K_{cp} + K_{pc} + K_{el})^2 - 4(K_{pc})(K_{el})} \right]$ |  | $\beta = \frac{1}{2} \left[ (K_{cp} + K_{pc} + K_{el}) - \sqrt{(K_{cp} + K_{pc} + K_{el})^2 - 4(K_{pc})(K_{el})} \right]$ |                           |
| $K_{cp} = \frac{CLd}{Vc}$  |  | $K_{pc} = \frac{CLd}{Vp}$   | $K_{el} = \frac{CLt}{Vc}$ |

For example for the drug meropenem:

- Vc (Liters) = 10.8 x (WT/70)
- Vp(Liters) = 12.6 x (WT/70)
- CLd (Liters/hour) = 18.6 x (WT/70)
- CLt (Liters/hour) = (10.2 + 2.08 x CLcr) x (WT/70) x 0.06
- fraction unbound (fup) = 0.98

Pseudo-code for finding roots:

**Step 1:** Test for special cases at steady-state:

**Step 2:** Compute fCmin

if fCmin > MIC then %fT>MIC = 100%

STOP

**Step 3:** Compute fCmax

if fCmax < MIC then %fT>MIC = 0%

STOP

**Step 4:** Else, compute t1 and t2

**Step 5:** Compute t1 (the time to go from fCmin to MIC  
Compute T2) using algorithm

**Step 6:** Compute t2 (time to go from fCmax to MIC) using  
algorithm

**Step 7:** compute %fT>MIC:

%fT>MIC = (t2-t1)/Tau x 100

Inputs:

## FIG 23 (con)

- *Drug: meropenem example*
  - Dose = 2000 milligrams
  - Duration of infusion ( $T_{inf}$ ) = 3 hours
  - $K_0 = \text{Dose}/T_{inf} = 2000 \text{ mg}/3 \text{ hr}$
  - Dosing interval ( $\tau$ ) = 8 hours
- Patient characteristics:
  - Creatinine clearance ( $CL_{cr}$ ) = 63.4 ml/min
  - Weight ( $WT$ ) = 86 kg
  - $MIC = 8 \text{ mg/L}$

Calculations:

- $V_c = 10.8 \times (86/70) = 13.2 \text{ L}$
- $V_p = 12.6 \times (86/70) = 15.48 \text{ L}$
- $CL_d = 18.6 \times (86/70) = 22.8 \text{ L/hr}$
- $CL_t = (10.2 + 2.08 \times 63.4) \times (86/70) \times 0.06 = 10.5 \text{ L/hr}$

$$K_{cp} = \frac{CL_d}{V_c} = \frac{22.8}{13.2} = 1.73$$

$$K_{pc} = \frac{CL_d}{V_p} = \frac{22.8}{15.48} = 1.47$$

$$K_{el} = \frac{CL_t}{V_c} = \frac{10.5}{13.2} = 0.796$$

$$\begin{aligned} \alpha &= \frac{1}{2} \left[ (K_{cp} + K_{pc} + K_{el}) + \sqrt{(K_{cp} + K_{pc} + K_{el})^2 - 4(K_{pc})(K_{el})} \right] \\ &= \frac{1}{2} \left[ (1.73 + 1.47 + 0.796) + \sqrt{(1.73 + 1.47 + 0.796)^2 - 4(1.47)(0.796)} \right] \\ &= 3.677 \end{aligned}$$

$$\begin{aligned} \beta &= \frac{1}{2} \left[ (K_{cp} + K_{pc} + K_{el}) - \sqrt{(K_{cp} + K_{pc} + K_{el})^2 - 4(K_{pc})(K_{el})} \right] \\ &= \frac{1}{2} \left[ (1.73 + 1.47 + 0.796) - \sqrt{(1.73 + 1.47 + 0.796)^2 - 4(1.47)(0.796)} \right] \\ &= 0.319 \end{aligned}$$

$$A = \frac{1}{V_c} \frac{\alpha - K_{pc}}{\alpha - \beta} = \frac{1}{13.2} \frac{3.677 - 1.47}{3.677 - 0.319} = 0.0497$$

$$B = \frac{1}{V_c} \frac{\beta - K_{pc}}{\beta - \alpha} = \frac{1}{13.2} \frac{0.319 - 1.47}{0.319 - 3.677} = 0.0260$$

### FIG 23 (con)

$$fC(t) = MIC$$

$$fC(t) - MIC = 0$$

- During infusion: where  $0 \leq t \leq T_{inf}$

$$f_{up} \times K_0 \left[ \frac{A}{\alpha} \left( 1 - e^{-\alpha t} + e^{-\alpha \tau} \frac{(1 - e^{-\alpha T_{inf}}) e^{-\alpha(t - T_{inf})}}{1 - e^{-\alpha \tau}} \right) + \frac{B}{\beta} \left( 1 - e^{-\beta t} + e^{-\beta \tau} \frac{(1 - e^{-\beta T_{inf}}) e^{-\beta(t - T_{inf})}}{1 - e^{-\beta \tau}} \right) \right] - MIC = 0$$

0.98

$$\times \frac{2000}{3} \left[ \frac{0.0497}{3.677} \left( 1 - e^{-3.677t} + e^{-3.677 \times 8} \frac{(1 - e^{-3.677 \times 3}) e^{-3.677(t-3)}}{1 - e^{-3.677 \times 8}} \right) + \frac{0.0260}{0.319} \left( 1 - e^{-0.319t} + e^{-0.319 \times 8} \frac{(1 - e^{-0.319 \times 3}) e^{-0.319(t-3)}}{1 - e^{-0.319 \times 8}} \right) \right] - 8 = 0$$

- After infusion: where  $t > T_{inf} < \tau$

$$f_{up} \times K_0 \left[ \frac{A}{\alpha} \left( \frac{(1 - e^{-\alpha T_{inf}}) e^{-\alpha(t - T_{inf})}}{1 - e^{-\alpha \tau}} \right) + \frac{B}{\beta} \left( \frac{(1 - e^{-\beta T_{inf}}) e^{-\beta(t - T_{inf})}}{1 - e^{-\beta \tau}} \right) \right] - MIC = 0$$

0.98

$$\times \frac{2000}{3} \left[ \frac{0.0497}{3.677} \left( \frac{(1 - e^{-3.677 \times 3}) e^{-3.677(t-3)}}{1 - e^{-3.677 \times 8}} \right) + \frac{0.0260}{0.319} \left( \frac{(1 - e^{-0.319 \times 3}) e^{-0.319(t-3)}}{1 - e^{-0.319 \times 8}} \right) \right] - 8 = 0$$

- Test for special cases at steady-state

- See if minimum concentration is greater than the MIC ( $fC_{min} > MIC$ )

- During infusion, minimum concentration would be at  $t=0$ :

- $fC(t = 0) =$

0.98 ×

$$\frac{2000}{3} \left[ \frac{0.0497}{3.677} \left( 1 - e^{-3.677(0)} + e^{-3.677 \times 8} \frac{(1 - e^{-3.677 \times 3}) e^{-3.677(0-3)}}{1 - e^{-3.677 \times 8}} \right) + \frac{0.0260}{0.319} \left( 1 - e^{-0.319(0)} + e^{-0.319 \times 8} \frac{(1 - e^{-0.319 \times 3}) e^{-0.319(0-3)}}{1 - e^{-0.319 \times 8}} \right) \right]$$

- $fC(t = 0) = 7.247 \text{ mg/L} < 8 \text{ mg/L}$

- See if maximum concentration is less than the MIC ( $fC_{max} < MIC$ )

## FIG 23 (con)

- Highest concentration would occur at the time the infusion ends ( $t=T_{inf}=3hr$ )

- $fC(t = 3) =$

$$0.98 \times$$

$$\frac{2000}{3} \left[ \frac{0.0497}{3.677} \left( 1 - e^{-3.677(3)} + e^{-3.677 \times 8} \frac{(1 - e^{-3.677 \times 3})e^{-3.677(3-3)}}{1 - e^{-3.677 \times 8}} \right) + \frac{0.0260}{0.319} \left( 1 - e^{-0.319(3)} + e^{-0.319 \times 8} \frac{(1 - e^{-0.319 \times 3})e^{-0.319(3-3)}}{1 - e^{-0.319 \times 8}} \right) \right]$$

- $fC(t = 3) = 44.48 \text{ mg/L} > 8 \text{ mg/L}$

- Since the above conditions have not been met,  $t_1$  and  $t_2$  can now be calculated:
  - $t_1 = 0.0163 \text{ hr}$  (using algorithm)
  - $t_2 = 7.69 \text{ hr}$  (using algorithm)

Thus,

$$\%fT > MIC = \frac{t_2 - t_1}{\tau} \times 100 = \frac{7.69 - 0.0163}{8} \times 100 = \mathbf{95.9\%}$$

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 16/14020

| <b>A. CLASSIFICATION OF SUBJECT MATTER</b><br>IPC(8) - A61P 31/00 (2016.01); G06Q 50/00 (2016.01)<br>CPC - A61K 31/00<br>According to International Patent Classification (IPC) or to both national classification and IPC  |  |  |   |  |   |   |  |   |   |  |   |  |  |
|---|--|--|---|--|---|---|--|---|---|--|---|--|--|
| <b>B. FIELDS SEARCHED</b><br>Minimum documentation searched (classification system followed by classification symbols)<br>IPC(8): A61P 31/00 (2016.01); G06Q 50/00 (2016.01)<br>CPC: A61K 31/00<br>Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched<br>CPC: A61K 31/00, C12Q 1/00, G01N 2333/00; G06F 19/00, G06F 19/10, G06F 19/24, G06F 19/12, G06F 19/707, G06F 19/709, G06F 19/3443, G06Q 10/00, G06Q 50/22, G06F 19/3437, G06Q 10/10 (keyword limited search below)<br>Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)<br>PatBase, Google Scholar, Google Patents; Search Terms: pharmacokinetic-pharmacodynamic, PK-PD, target, probability, odds, likelihood, prospect, expectation, infection*, pathogen*, treatment*, drug*, therap*, model*, patient information, ICPD TECHNOLOGIES, AMBROSE, BHAVNANI, RUBINO, percentage*, mobile   |  |  |   |  |   |   |  |   |   |  |   |  |  |
| <b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>   |  |  |   |  |   |   |  |   |   |  |   |  |  |
| <table border="1"> <thead> <tr> <th>Category*</th> <th>Citation of document, with indication, where appropriate, of the relevant passages</th> <th>Relevant to claim No.</th> </tr> </thead> <tbody> <tr> <td>Y</td> <td>US 2014/0329740 A1 (YEAMAN et al.) 06 November 2014 (06.11.2014) entire document especially Abstract, para [0035]-[0038], para [0049]-[0050], para [0061]-[0062], [0129]-[0130], para [0179]-[0180]</td> <td>1-20</td> </tr> <tr> <td>Y</td> <td>US 2012/0197188 A1 (Syroid et al.) 02 August 2012 (02.08.2012) entire document especially Abstract, para [0011], para [0017], para [0038]-[0042], para [0050]-[0051]</td> <td>1-20</td> </tr> <tr> <td>A</td> <td>US 2012/0035097 A1 (McKay et al.) 09 February 2012 (09.02.2012) entire document</td> <td>1-20</td> </tr> </tbody> </table>  | Category*  | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No.   | Y  | US 2014/0329740 A1 (YEAMAN et al.) 06 November 2014 (06.11.2014) entire document especially Abstract, para [0035]-[0038], para [0049]-[0050], para [0061]-[0062], [0129]-[0130], para [0179]-[0180] | 1-20  | Y  | US 2012/0197188 A1 (Syroid et al.) 02 August 2012 (02.08.2012) entire document especially Abstract, para [0011], para [0017], para [0038]-[0042], para [0050]-[0051]    | 1-20  | A  | US 2012/0035097 A1 (McKay et al.) 09 February 2012 (09.02.2012) entire document | 1-20   |  |
| Category*   | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No.  |   |  |   |   |  |   |   |  |   |  |  |
| Y   | US 2014/0329740 A1 (YEAMAN et al.) 06 November 2014 (06.11.2014) entire document especially Abstract, para [0035]-[0038], para [0049]-[0050], para [0061]-[0062], [0129]-[0130], para [0179]-[0180]  | 1-20   |   |  |   |   |  |   |   |  |   |  |  |
| Y   | US 2012/0197188 A1 (Syroid et al.) 02 August 2012 (02.08.2012) entire document especially Abstract, para [0011], para [0017], para [0038]-[0042], para [0050]-[0051]   | 1-20   |   |  |   |   |  |   |   |  |   |  |  |
| A   | US 2012/0035097 A1 (McKay et al.) 09 February 2012 (09.02.2012) entire document  | 1-20   |   |  |   |   |  |   |   |  |   |  |  |
| <input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/>  |  |  |   |  |   |   |  |   |   |  |   |  |  |
| <table border="0"> <tr> <td>* Special categories of cited documents:</td> <td>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>"A" document defining the general state of the art which is not considered to be of particular relevance</td> <td>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>"E" earlier application or patent but published on or after the international filing date</td> <td>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>"&amp;" document member of the same patent family</td> </tr> <tr> <td>"O" document referring to an oral disclosure, use, exhibition or other means</td> <td></td> </tr> <tr> <td>"P" document published prior to the international filing date but later than the priority date claimed</td> <td></td> </tr> </table> |  | * Special categories of cited documents:   | "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention | "A" document defining the general state of the art which is not considered to be of particular relevance | "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone                        | "E" earlier application or patent but published on or after the international filing date | "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art | "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) | "&" document member of the same patent family | "O" document referring to an oral disclosure, use, exhibition or other means |   | "P" document published prior to the international filing date but later than the priority date claimed |  |
| * Special categories of cited documents:  | "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  |  |   |  |   |   |  |   |   |  |   |  |  |
| "A" document defining the general state of the art which is not considered to be of particular relevance  | "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone   |  |   |  |   |   |  |   |   |  |   |  |  |
| "E" earlier application or patent but published on or after the international filing date   | "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art |  |   |  |   |   |  |   |   |  |   |  |  |
| "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)   | "&" document member of the same patent family  |  |   |  |   |   |  |   |   |  |   |  |  |
| "O" document referring to an oral disclosure, use, exhibition or other means  |  |  |   |  |   |   |  |   |   |  |   |  |  |
| "P" document published prior to the international filing date but later than the priority date claimed  |  |  |   |  |   |   |  |   |   |  |   |  |  |
| Date of the actual completion of the international search<br>02 March 2016 (02.03.2016)   | Date of mailing of the international search report<br><b>28 MAR 2016</b>   |  |   |  |   |   |  |   |   |  |   |  |  |
| Name and mailing address of the ISA/US<br>Mail Stop PCT, Attn: ISA/US, Commissioner for Patents<br>P.O. Box 1450, Alexandria, Virginia 22313-1450<br>Facsimile No. 571-273-8300   | Authorized officer:<br>Lee W. Young<br>PCT Helpdesk: 571-272-4300<br>PCT OSP: 571-272-7774   |  |   |  |   |   |  |   |   |  |   |  |  |